Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.

NCT05008016 | Completed

• 1 other identifier: Anaesthesia and Resuscitation
• Study Type: observational
• Target: 582
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory Clinique cases specially patient with pulmonary bacterienne infection . Materials and methods the investigatore had retrospectively reviewed the electronic records and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of severity and high mortality .

Conditions

the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients

Keywords

COVID; Procalcitonine; Mortality

Outcome Measures

Primary Outcomes (1)

• Procalcitonin is a marker of mortality

  as a cutoff 0.5 ng/ml Procalcitonin could be used as mortality factors

  through study completion, an average of 8 mounths

Study Arms (1)

Procalcitonine analysed

The invistagatore had analysed the Procalcitonine of patient that survived and the non Survived frome COVID infection in Intensive care departement

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

-582 patient with the SARS COV 2 virus, in the Resuscitation Service of the Mohammed VI University Hospital Center oujda, MAroc

You may qualify if:

• Clinical diagnosis of SARS COV2 infection needed admission in ICU .

You may not qualify if:

• patient under 15 ans

Sponsors & Collaborators

• Mohammed VI University Hospital: lead

Study Sites (1)

younes Oujidi

Berkane, 9999, Morocco

Location

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 11, 2021
• First Posted: August 17, 2021
• Study Start: January 1, 2020
• Primary Completion: January 1, 2020
• Study Completion: January 31, 2021
• Last Updated: August 17, 2021

Record last verified: 2021-08

Data Sharing

• IPD Sharing: Will not share

Locations

MO (1)